Clarifying the causal contrast: An empirical example applying the prevalent new user study design.
Jessica C YoungMichael A Webster-ClarkShahar ShmuelElizabeth M GarryPanagiotis MavrosTil StürmerCynthia J GirmanPublished in: Pharmacoepidemiology and drug safety (2024)
When analyses were conducted only among incident new users, GLP-1 RA had a protective effect. However, among switchers from SU to GLP-1 RA, the effect estimates substantially shifted toward the null. Combining patients with varying treatment histories can result in poor confounding control and camouflage important heterogeneity.